WEERT, The Netherlands,
October 22, 2013 /PRNewswire/ --
Global pharmaceutical chemistry leader Cambridge Major
Laboratories Europe, B.V. (CML-Europe) is pleased to announce the
successful completion of its first Food and Drug Administration
inspection. The inspection included a pre-approval inspection and
general quality systems audit and concluded with no Form 483 being
issued.
(Logo:
http://photos.prnewswire.com/prnh/20130723/629764-a )
"This successful FDA inspection represents a major milestone for
the CML-Europe facility," said Peter van
Tilburg, President of CML-Europe. "We place Quality above
all else, and I am so proud that the dedication and performance of
the CML-Europe team resulted in this successful outcome."
The successful inspection is the culmination of efforts to
demonstrate CML-Europe's ability to supply world-class development
services and niche commercial APIs to its growing customer
base.
"CML-Europe will always be committed to quality and strong
leadership, and this commitment is evidenced by two significant
recent hires," said Peter van
Tilburg. In September 2013,
CML-Europe hired Dr. Marcel Schreuder Goedheijt as Director
Operations, and Mr. Jan Douwstra as
Head of Production. Dr. Schreuder Goedheijt brings a wealth of
chemical pharmaceutical and business experience from his previous
positions at DSM, DSM Pharma Chemicals, MSD and Diosynth BV. Mr.
Douwstra held previous positions at the Academic Medical Centre,
Amsterdam and St. Radboud
University Medical Centre, Nijmegen, as well as Abbott Healthcare
B.V., Solvay Pharmaceuticals B.V. Weesp, and Smit & Zoon B.V.
Amersfoort.
Cambridge Major Laboratories, Inc. announced its intent to merge
with AAIPharma Services, Corp. on October 2,
2013.
About Cambridge Major Laboratories,
Inc.
Cambridge Major Laboratories, Inc. (CML) is a leading global
chemistry outsourcing partner to the pharmaceutical and
biotechnology industries. The Company produces pharmaceutical
intermediates and Active Pharmaceutical Ingredients (API), from
early preclinical development to commercial manufacturing.
Operating from FDA-inspected facilities in the US and Europe, CML is organized along five key
Centers of Excellence, including: Process Chemistry, GMP
Manufacturing, Solid State Chemistry, Analytical Services, and
Quality/Regulatory Compliance. CML is a portfolio company of
American Capital, Ltd. (NASDAQ: ACAS).
For more information on the company, visit
http://www.c-mlabs.com
About AAIPharma Services Corp.
AAIPharma Services Corp. is a leading provider of contract
services that support all phases of drug development. The company's
wide array of capabilities includes analytical and formulation
development, material testing services, microbiology, clinical and
commercial contract manufacturing, pharmaceutical packaging, and
stability services. Serving more than 600 clients around the globe
and headquartered in Wilmington,
N.C., AAIPharma is a portfolio company of Water Street
Healthcare Partners, a strategic investor focused exclusively on
health care.
For more information on the company, visit
http://www.aaipharma.com
Media Contacts:
Kim Black-Washington (CML)
k.black-washington@c-mlabs.com +1-262-955-4715
Jeff A. Parrott, Ph.D. (AAIPharma
Services Corp.) media_relations@aaipharma.com
Related Links: Cambridge Major Laboratories Home Page
http://www.c-mlabs.com
AAIPharma Home Page
http://www.aaipharma.com